Bedel Financial Consulting »

Relmada Therapeutics shares owned by Bedel Financial Consulting

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by Bedel Financial Consulting from 13F filings

Historical chart of Bedel Financial Consulting investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by Bedel Financial Consulting consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by Bedel Financial Consulting

Quarter filed Position value Share count Share price at filing
2023-09-30 $30k 10k 3.00

More positions owned by Bedel Financial Consulting

Eli Lilly & Co. (LLY)
Vanguard Mun Bd Fds Tax Exempt Bd (VTEB)
Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Apple (AAPL)
Dimensional Etf Trust Emgr Cre Eqt Mng (DFAE)
Microsoft Corporation (MSFT)
Ishares Tr Eafe Grwth Etf (EFG)
Ssga Active Etf Tr Spdr Tr Tactic (TOTL)
Innovator Etfs Tr Us Eqt Pwr Buf (PAPR)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Capital Group Growth Etf Shs Creation Uni (CGGR)
Global X Fds Rate Preferred (PFFV)
JPMorgan Chase & Co. (JPM)
Ishares Tr MRGSTR MD CP GRW (IMCG)

View all positions for Bedel Financial Consulting

Top funds holding Relmada Therapeutics

Franklin Resources
Vanguard Group
Acadian Asset Management
Palo Alto Investors
Deep Track Capital
Millennium Management
BlackRock
Vestal Point Capital
Opaleye Management
Jpmorgan Chase & Co
Geode Capital Management
Two Sigma Advisers
Deutsche Bank Aktiengesellschaft
Bank of America Corporation
Two Sigma Investments

View all funds holding Relmada Therapeutics